Cytomegalovirus (CMV) disease after intestinal and multivisceral transplantation is common (40% in this cohort) and can be associated with systemic disease, end-organ disease, and adverse outcomes.

CMV disease is more common (up to 90%) in cases of pre-transplantation serologic mismatch, especially “donor-positive, recipient-negative.”

One-third of patients with CMV viremia develop evidence of in vitro virologic resistance, which presents significant clinical challenges to management.

There is an urgent need for novel therapies to treat CMV infection which are likely to include both pharmacologic strategies and cell-based therapies such as adoptive T-cell transfer.